Protagonist Therapeutics, Inc.
PTGXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Protagonist Therapeutics, Inc. (PTGX) is listed under Biotechnology. At a $9.43B market cap, Protagonist Therapeutics, Inc. ranks as a mid-cap company within healthcare. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera.
Market Cap
$9.43B
Beta
1.79
P/E (TTM)
141.48
P/E (Fwd)
-731.71
EPS (TTM)
$1.03
EPS (Fwd)
$-0.20
ROE
11.0%
ROA
4.5%
Cash
$782.6M
Total Debt
$9.2M
Free CF
$96.1M
52W Change
149.7%
Annual Financials
Cash vs Debt
Where PTGX stands vs its 150-day and 200-day moving averages
As of the August 27, 2026 close, PTGX finished 38.10% above its 150-day moving average ($109.70) and 45.88% above its 200-day moving average ($103.85). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PTGX overbought or oversold?
At the August 27, 2026 close, PTGX's RSI(14) was 57.7, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $782.6M in cash and $9.2M in debt, PTGX maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company generates $96.1M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 11.0% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 4.5% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $26.6M (2022) to $46.0M (2025), reflecting a 73% increase over the period.
A beta of 1.79 means PTGX is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. With cash comfortably exceeding debt, PTGX has financial flexibility that may help navigate uncertain periods. The elevated P/E ratio means the stock is priced for significant future growth. If earnings disappoint, the price correction could be sharp. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing PTGX.